our portfolio

InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application.

InflaRx focuses on the development of first-in-class monoclonal antibodies targeting activation products of the complement system for application in life threatening inflammatory diseases and certain orhan drug indications.

In May 2014, Affentranger Associates sold its position in InflaRx to a group of private investors.